⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3631709 | 0.85 | AGTR1 (0.58) | — | |
| SCHEMBL1258063 | 0.84 | — | — | |
| SCHEMBL3625358 | 0.79 | AGTR2 (0.61) | — | |
| SCHEMBL8944669 | 0.77 | — | — | |
| SCHEMBL9339210 | 0.77 | — | — | |
| SCHEMBL29308431 | 0.76 | AGTR1 (0.53) | — | |
| SCHEMBL621 | 0.76 | — | — | |
| SCHEMBL9448627 | 0.76 | — | — | |
| SCHEMBL13473656 | 0.76 | AGTR1 (0.53) | — | |
| SCHEMBL8394915 | 0.76 | EDNRA (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9273008-B2 | Dual-acting imidazole antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-03-01 | — | — | US | disclosed |
| US-9150514-B2 | Dual-acting antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-10-06 | — | — | US | disclosed |
| US-20150191435-A1 | DUAL-ACTING IMIDAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-07-09 | — | — | US | disclosed |
| US-20150065543-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-03-05 | — | — | US | disclosed |
| EP-2146963-B1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R & D IP LLC (US) | 2014-12-17 | — | — | EP | disclosed |
| US-8895755-B2 | Intermediates for preparing dual-acting benzyl triazole antihypertensive agents having angiotensin II type I receptor antagonist activity and neprilysin-inhibition activity | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-11-25 | — | — | US | disclosed |
| US-8664254-B2 | Dual-acting imidazole antihypertensive agents | THERAVANCE, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-20140024835-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-8569351-B2 | Dual-acting benzyl triazole antihypertensive agents having angiotensin II type receptor antagonist activity and neprilysin-inhibition activity | THERAVANCE, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20130245087-A1 | DUAL-ACTING IMIDAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-09-19 | — | — | US | disclosed |
| US-20130096162-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-04-18 | — | — | US | disclosed |
| US-8349875-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8344013-B2 | Dual-acting imidazole antihypertensive agents | THERAVANCE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120264752-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-8236846-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20120165381-A1 | DUAL-ACTING IMIDAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| EP-2146963-A2 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | Theravance, Inc. (US) | 2010-01-27 | — | — | EP | disclosed |
| US-20090023228-A1 | Dual-acting Imidazole antihypertensive agents | THERAVANCE, INC. | 2009-01-22 | — | — | US | disclosed |
| WO-2008133896-A2 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
| US-20080269305-A1 | R)-N-{2-Butyl-3-[2'-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl]-3H-imidazol-4-ylmethyl}-2-(2-hydroxycarbamoyl-3-phenyl-propionylamino)succinamic Acid; AT1 receptor antagonist and neprilysin (NEP) enzyme inhibition activity; hypertension, heart failure | THERAVANCE, INC. | 2008-10-30 | — | — | US | disclosed |